BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sontini V, Gozzini A, Scappini B, Grossi A, Ferrini PR. Searching for the Magic Bullet Against Cancer: The Butyrate Saga. Leukemia & Lymphoma 2009;42:275-89. [DOI: 10.3109/10428190109064584] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors. Epilepsia 2004;45:737-44. [DOI: 10.1111/j.0013-9580.2004.00104.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 117] [Article Influence: 7.4] [Reference Citation Analysis]
2 Kutlu Ö, Cansu A, Karagüzel E, Gürgen SG, Koç Ö, Gür M, Özgür GK. Effect of valproic acid treatment on penile structure in prepubertal rats. Epilepsy Research 2012;99:306-11. [DOI: 10.1016/j.eplepsyres.2011.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
3 Brioschi AM, Calderoni S, Zara GP, Priano L, Gasco MR, Mauro A. Solid lipid nanoparticles for brain tumors therapy. Nanoneuroscience and Nanoneuropharmacology. Elsevier; 2009. pp. 193-223. [DOI: 10.1016/s0079-6123(08)80011-8] [Cited by in Crossref: 9] [Article Influence: 0.7] [Reference Citation Analysis]
4 Tronstad KJ, Berge K, Berge RK, Bruserud Ø. Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opinion on Therapeutic Targets 2005;7:663-77. [DOI: 10.1517/14728222.7.5.663] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
5 Dai W, Liu S, Zhang J, Pei M, Xiao Y, Li J, Hong L, Lin J, Wang J, Wu X, Liu G, Chen Y, Wang Y, Lin Z, Yang Q, Zhi F, Li G, Tang W, Li A, Xiang L, Wang J. Vorinostat triggers miR-769-5p/3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer. Cancer Lett 2021;521:196-209. [PMID: 34481934 DOI: 10.1016/j.canlet.2021.09.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fotovati A, Abu-ali S, Kage M, Shirouzu K, Yamana H, Kuwano M. N-myc Downstream-regulated Gene 1 (NDRG1) a Differentiation Marker of Human Breast Cancer. Pathol Oncol Res 2011;17:525-33. [DOI: 10.1007/s12253-010-9342-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
7 Soares AM, Hungerford G, Costa SP, Gonçalves MST. Photoactivatable prodrugs of butyric acid based on new coumarin fused oxazole heterocycles. Dyes and Pigments 2017;137:91-100. [DOI: 10.1016/j.dyepig.2016.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H, Cinatl J Jr. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004;65:520-7. [PMID: 14978230 DOI: 10.1124/mol.65.3.520] [Cited by in Crossref: 156] [Cited by in F6Publishing: 135] [Article Influence: 8.7] [Reference Citation Analysis]
9 Li X, Luo HS, Li F. Effect of sodium butyrate on the expression of cathepsins D. Shijie Huaren Xiaohua Zazhi 2003; 11(10): 1508-1510 [DOI: 10.11569/wcjd.v11.i10.1508] [Reference Citation Analysis]
10 Sena CFA, Apolinário LS, Duarte JA, dos Santos GC, Monteiro LOF, de Oliveira MC, Leite EA, de Oliveira RB. Preformulation and formulation development of a bioactive nitroaromatic compound. J Nanopart Res 2017;19. [DOI: 10.1007/s11051-017-4073-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm. 2004;58:673-680. [PMID: 15451544 DOI: 10.1016/j.ejpb.2004.03.026] [Cited by in Crossref: 103] [Cited by in F6Publishing: 102] [Article Influence: 6.1] [Reference Citation Analysis]
12 Santini V, Gozzini A, Bosi A. Treatment Options in Myelodysplastic Syndromes: A New Frontier. Journal of Chemotherapy 2013;20:291-6. [DOI: 10.1179/joc.2008.20.3.291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Atadja PW. HDAC inhibitors and cancer therapy. Prog Drug Res 2011;67:175-95. [PMID: 21141730 DOI: 10.1007/978-3-7643-8989-5_9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 20] [Article Influence: 0.2] [Reference Citation Analysis]
14 Grebeňová D, Kuželová K, Pluskalová M, Pešlová G, Halada P, Hrkal Z. The proteomic study of sodium butyrate antiproliferative/cytodifferentiation effects on K562 cells. Blood Cells, Molecules, and Diseases 2006;37:210-7. [DOI: 10.1016/j.bcmd.2006.08.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
15 Eyal S, Yagen B, Shimshoni J, Bialer M. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochemical Pharmacology 2005;69:1501-8. [DOI: 10.1016/j.bcp.2005.02.012] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
16 Togher KL, Togher KL, O'Keeffe MM, O'Keeffe MM, Khashan AS, Khashan AS, Gutierrez H, Gutierrez H, Kenny LC, Kenny LC, O'Keeffe GW, O'Keeffe GW. Epigenetic regulation of the placental HSD11B2 barrier and its role as a critical regulator of fetal development. Epigenetics 2014;9:816-22. [PMID: 24717516 DOI: 10.4161/epi.28703] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
17 Rovida E, Gozzini A, Barbetti V, Giuntoli S, Santini V, Dello Sbarba P. The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells. Br J Haematol 2006;135:653-9. [PMID: 17054427 DOI: 10.1111/j.1365-2141.2006.06365.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
18 Serpe L, Laurora S, Pizzimenti S, Ugazio E, Ponti R, Canaparo R, Briatore F, Barrera G, Gasco MR, Bernengo MG, Eandi M, Zara GP. Cholesteryl butyrate solid lipid nanoparticles as a butyric acid pro-drug: effects on cell proliferation, cell-cycle distribution and c-myc expression in human leukemic cells. Anticancer Drugs 2004;15:525-36. [PMID: 15166628 DOI: 10.1097/01.cad.0000127329.83568.15] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
19 Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 2008;13:230-54. [PMID: 18305415 DOI: 10.3390/molecules13020230] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
20 Bareket L, Rephaeli A, Berkovitch G, Nudelman A, Rishpon J. Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs. Bioelectrochemistry 2010;77:94-9. [PMID: 19643682 DOI: 10.1016/j.bioelechem.2009.06.016] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
21 Tischler JL, Abuaita B, Cuthpert SC, Fage C, Murphy K, Saxe A, Furr EB, Hedrick J, Meyers J, Snare D, Zand AR. Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors. J Enzyme Inhib Med Chem 2008;23:549-55. [PMID: 18608778 DOI: 10.1080/14756360701715703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]